Zenas' stock sinks in wake of autoimmune phase 3 data despite primary endpoint hit
Zenas' stock sinks in wake of autoimmune phase 3 data despite primary endpoint hit
Body unavailable. Use the original source.
Zenas' stock sinks in wake of autoimmune phase 3 data despite primary endpoint hit